Lundbeck’s bocunebart met primary endpoints in the Phase IIb PROCEED trial, reducing migraine days and supporting PACAP inhibition as a novel preventive strategy.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Lundbeck announced positive topline results from the Phase IIb PROCEED trial (NCT06323928) evaluating bocunebart (Lu AG09222), an investigational monoclonal antibody targeting pituitary adenylate cyclase-activating polypeptide (PACAP), for migraine prevention.
Findings presented at the American Headache Society (AHS) Congress 2026 showed that intravenous bocunebart significantly reduced monthly migraine days versus placebo in patients with one to four prior preventive treatment failures, supporting PACAP inhibition as a novel approach to prevention.
The results add to growing evidence that the PACAP pathway is a promising therapeutic target for patients with migraine who continue to experience inadequate disease control despite available preventive therapies.
Targeting the PACAP Pathway
Bocunebart acts on the PACAP pathway, a neuropeptide implicated in migraine pathophysiology through mechanisms distinct from calcitonin gene-related peptide (CGRP). This differentiated biology positions bocunebart as a potential alternative for patients deriving insufficient benefit from currently approved preventive therapies, including anti-CGRP agents.
Migraine remains one of the most disabling neurological disorders worldwide, imposing a major burden on daily functioning, productivity, and quality of life. Patients who fail multiple preventive therapies often have limited options, underscoring the need for new mechanisms of action.
Efficacy Results
In the intravenous arm, bocunebart met the primary endpoint. Patients experienced a mean reduction of 4.24 monthly migraine days from baseline over Weeks 1–12, compared with 2.86 days for placebo, corresponding to a statistically significant treatment difference of 1.38 days (p=0.0178).
The effect was stronger in patients with severe chronic migraine and prior preventive failures. Across pooled analyses from Lundbeck’s Phase II program, bocunebart reduced monthly migraine days by 5.94 versus 3.63 for placebo, yielding a 2.31-day difference (p<0.001). These findings suggest greater benefit among patients with higher disease burden.
Trial Design and Scope
The PROCEED study assessed efficacy, safety, and tolerability of bocunebart administered once monthly for three months. A total of 429 patients across 14 countries participated in the intravenous arm after futility was declared in the subcutaneous arm.
The randomized, double-blind, placebo-controlled trial enrolled patients with migraine who had failed one to four preventive therapies. The primary endpoint measured change from baseline in monthly migraine days over Weeks 1–12.
Safety and Tolerability
Safety findings were consistent with earlier studies. Bocunebart was generally well tolerated, with no new safety signals identified. Nasopharyngitis was the most frequent treatment-emergent adverse event, reported in at least 5% of treated patients.
Emerging Role of PACAP Inhibition
Jessica Ailani, MD, coordinating investigator of PROCEED, said the findings are encouraging given the number of patients who remain inadequately controlled despite advances in treatment. She noted that emerging evidence supports bocunebart as a potential new preventive option.
Johan Luthman, Executive Vice President and Head of R&D at Lundbeck, added that the results strengthen confidence in targeting the PACAP pathway and support continued development.
Co‑Administration with Ubrogepant
Phase I data showed bocunebart was well tolerated when administered with ubrogepant. Together with prior findings involving triptan co-administration, these results support compatibility with commonly prescribed acute migraine therapies.
Next‑Phase Development Plans
Following the positive PROCEED results, Lundbeck is preparing for further clinical development of bocunebart in migraine prevention. The company is positioning the therapy as a potential new treatment class targeting the PACAP pathway, aiming to expand options for patients inadequately controlled on existing preventive therapies. Phase III planning will be critical to establish regulatory submission timelines.
Reference
About the Writer
Chikkula Pavan Kumar (LinkedIn), PharmD is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.